Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Drug Profile

Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Alternative Names: ARC AMG1; ARC HIF2; ARC LPA; ARC-F12; ARO-AMG1; ARO-F12; ARO-HBV; ARO-LPA; RNAi ARC-LPA

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Mirus Bio Corporation
  • Developer Arrowhead Pharmaceuticals; Roche Madison
  • Class Small interfering RNA
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Cardiovascular disorders; Hepatitis B; Hereditary angioedema; Liver cancer; Renal cell carcinoma; Solid tumours; Thromboembolism
  • No development reported Hyperlipidaemia; Respiratory tract disorders

Most Recent Events

  • 14 Nov 2016 Pharmacodynamics data from preclinical studies in Cardiovascular disorders and Thromboembolism released by Arrowhead Pharmaceuticals
  • 14 Nov 2016 Arrowhead Pharmaceuticals plans clinical trials for Hereditary angioedema and Thromboembolism
  • 29 Sep 2016 Arrowhead Pharmaceuticals and Amgen enter into an options agreement for RNAi therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top